Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Fluzoparib in Subjects With Impaired Kidney Function
NCT05032235Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluzoparib in ovarian cancer (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax) of Fluzoparib, Area Under the Curve (AUC0-t) of Fluzoparib and 4 more. Started Nov 2021; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05032235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032235.